Studies on Cognitive Screening, Memory, and Alzheimer's disease by J. Wesson Ashford, M.D., Ph.D.

ARTICLES REFERENCED ON "PUBMED"  to  Ashford JW or Wesson Ashford  - several PDF files available

See also NIH: Over 180 references.

Articles related to MemTrax, a computerized on-line episodic memory testing using a Continuous Recognition Task format

Clifford JO Jr, Anand S, Tarpin-Bernard F, Bergeron MF, Ashford CB, Bayley PJ, Ashford JW. Episodic memory assessment: effects of sex and age on performance and response time during a continuous recognition task. Front Hum Neurosci. 2024 Apr 4;18:1304221. doi: 10.3389/fnhum.2024.1304221.    PDF

Liu Y, Wu L, Chen W, Su F, Liu G, Zhou X, Ashford CB, Li F, Ashford JW, Pei Z, Xian W. The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2024 Mar;120:106016. doi: 10.1016/j.parkreldis.2024.106016.    PDF

Liu W, Yu L, Deng Q, Li Y, Lu P, Yang J, Chen F, Li F, Zhou X, Bergeron MF, Ashford JW, Xu Q. Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China. Alzheimers Dement. 2023 Aug 31. doi: 10.1002/alz.13430.    PDF

Zhao X, Dai S, Zhang R, Chen X, Zhao M, Bergeron MF, Zhou X, Zhang J, Zhong L, Ashford JW, Liu X. Using MemTrax memory test to screen for post-stroke cognitive impairment after ischemic stroke: a cross-sectional study. Front Hum Neurosci. 2023 Jul 17;17:1195220. doi: 10.3389/fnhum.2023.1195220    PDF

Chen W, Lin C, Su F, Fang Y, Liu G, Chen YC, Zhou X, Yao X, Ashford CB, Li F, Ashford JW, Fu QL, Pei Z. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers. J Alzheimers Dis. 2023;94(3):1093-1103. doi: 10.3233/JAD-230182.    PDF

Ashford JW, Clifford JO, Bergeron MF. Advancing screening for cognitive impairment: the memtrax continuous recognition test. Aging (Albany NY). 2023 Jun 14;15(12):5230-5231. doi: 10.18632    PDF

Ashford JW, Clifford JO, Anand S, Bergeron MB, Ashford CB, Bayley PJ. Correctness and Response Time Distributions in the MemTrax Continuous Recognition Task: Analysis of Strategies and a Reverse-Exponential Model. Front Aging Neurosci. doi:10.3389/fnagi.2022.1005298.   PDF - Frontiers site, 18 megs   PDF - MedaFile, 18 megs   PDF - 2 megs version

Liu X, Chen X, Zhou X, Shang Y, Xu F, Zhang J, He J, Zhao F, Du B, Wang X, Zhang Q, Zhang W, Bergeron MF, Ding T, Wesson Ashford J, Zhong L. J Alzheimers Dis. Validity of the MemTrax Memory Test Compared to the Montreal Cognitive Assessment in the Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease in a Chinese Cohort. 2021 Feb 24. doi: 10.3233    PDF

Bergeron MF, Landset S, Zhou X, Ding T, Khoshgoftaar TM, Zhao F, Du B, Chen X, Wang X, Zhong L, Liu X, Ashford JW. Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment. J Alzheimers Dis. 2020;77(4):1545-1558. doi: 10.3233/JAD-191340.    PDF

Zhou X, Ashford JW. Advances in screening instruments for Alzheimer's disease. Aging Med (Milton). 2019 May 31;2(2):88-93. doi: 10.1002    PDF

Bergeron MF, Landset S, Tarpin-Bernard F, Ashford CB, Khoshgoftaar TM, Ashford JW. Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification. J Alzheimers Dis. 2019;70(1):277-286.    PDF

Ashford JW, Tarpin-Bernard F, Ashford CB, Ashford MT. A Computerized Continuous-Recognition Task for Measurement of Episodic Memory. J Alzheimers Dis. 2019;69(2):385-399.    PDF

Cholerton B, Weiner MW, Nosheny RL, Poston KL, Mackin RS, Tian L, Ashford JW, Montine TJ. Cognitive Performance in Parkinson's Disease in the Brain Health Registry. J Alzheimers Dis. 2019;68(3):1029-1038.    PDF

van der Hoek MD, Nieuwenhuizen A, Keijer J, Ashford JW. The MemTrax Test Compared to the Montreal Cognitive Assessment Estimation of Mild Cognitive Impairment. J Alzheimers Dis. 2019;67(3):1045-1054.    PDF

Ashford JW, Schmitt FA, Smith CJ, Kumar V, Askari N. Assessment of Cognitive Impairment, Alzheimer's Disease, and Other Forms of Dementia. In: Ethnicity and the Dementias. G. Yeo, L.A. Gardner, D. Gallagher-Thompson, eds, Routledge, Taylor & Francis Group. 2019.   PDF

Ashford JW, Schmitt F, Kumar V. Diagnosis of Alzheimer's Disease. In Advances in the Diagnosis and Treatment of Alzheimer's Disease. Kumar V. Eisdorfer C. eds, Springer Publishing Company, New York, 1998:111-151.   PDF

Articles related to screening for cognitive impairment, dementia, and Alzheimer's disease and
measuring the continuum of cognitive decline associated with Alzheimer's disease

Ashford JW, Schmitt FA, Bergeron MF, Bayley PJ, Clifford JO, Xu Q, Liu X, Zhou X, Kumar V, Buschke H, Dean M, Finkel SI, Hyer L, Perry G. Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. J Alzheimers Dis. 2022 Apr 11. doi: 10.3233/JAD-220211.    PDF
   See supplement for scales.

Bayley PJ, Kong JY, Mendiondo M, Lazzeroni LC, Borson S, Buschke H, Dean M, Fillit H, Frank L, Schmitt FA, Peschin S, Finkel S, Austen M, Steinberg C, Ashford JW. Findings from the National Memory Screening Day program. J Am Geriatr Soc. 2015 Feb;63(2):309-14.    PDF

Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, McCarten JR, Morris JC, Salmon DP, Schmitt FA, Stefanacci RG, Mendiondo MS, Peschin S, Hall EJ, Fillit H, Ashford JW. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement. 2013 Mar;9(2):151-9.    PDF

Ashford JW. Screening for Memory Disorder, Dementia, and Alzheimer's disease. Aging Health. (2008) 4(4):399-432.    PDF

Ashford JW, Borson S. Primary care screening for dementia and mild cognitive impairment. JAMA. 2008 Mar 12;299(10):1132-3.    PDF

Ashford JW, Kraemer HC, Tinklenber JR, O'Hara R, Taylor JL, Yesavage JA. Statistical and pharmacoeconomic issues for Alzheimer's screening. Alzheimer's & Dementia. (2007) April;3:126.    PDF

Ashford JW, Borson S, O'Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H. Fillit H. Should older adults be screened for dementia? It is important to screen for evidence of dementia. Alzheimer?s & Dementia. (2007) April;3:75-80.    PDF

Ashford JW, Borson S, O'Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H. Should older adults be screened for dementia? Alzheimer's & Dementia. (2006) April;2:76-85.    PDF

Schmitt FA, Mendiondo MS, Kryscio RJ, Ashford JW. A brief Alzheimers screen for clinical practice. Research Practice in Alzheimers Disease (2006) 11:1-4.    PDF

Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Designing a brief Alzheimer screen (BAS). J Alzheimers Dis. 2003 Dec 5:391-398.    PDF

Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep. 2001 Feb;3(1):20-8.    PDF

Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med. 2000 Jun 15-30;19(11-12):1607-16.    PDF

Ashford, J.W., Coburn, K.L., Fuster, J.M. Functional Cognitive Networks in Primates. In: Parks, R.W. and Levine, D.S. Fundamentals of Neural Networks: Neuropsychology and Cognitive Neuroscience. The MIT Press: Cambridge, Mass, 1998:33-60.    DOC

Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-6.

Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study.
J Am Geriatr Soc. 1996 Jun;44(6):675-81.

Ashford JW, Shan M, Butler S, Rajasekar A, Schmitt FA. Temporal quantification of Alzheimer's disease severity: 'time index' model. Dementia. 1995 Sep-Oct;6(5):269-80.    PDF

Ashford JW, Kolm P, Colliver JA, Bekian C, Hsu LN. Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. J Gerontol. 1989 Sep;44(5):P139-46. PDF

Small GW, Kuhl DE, Fujikawa DG, Ashford JW. Clinical characterization of Alzheimer's disease: reliability of 'age at onset' and a new descriptor, 'age at shift'.
J Geriatr Psychiatry Neurol. 1988 Oct-Dec;1(4):207-11.

Articles related to APOE genotype

Smith CJ, Ashford JW. Apolipoprotein ɛ4-Associated Protection Against Pediatric Enteric Infections Is a Survival Advantage in Pre-Industrial Populations. J Alzheimers Dis. 2023;93(3):907-918. doi: 10.3233 PDF

Smith CJ, Ashford JW, Perfetti TA. Putative Survival Advantages in Young Apolipoprotein e4 Carriers are Associated with Increased Neural Stress. J Alzheimers Dis. 2019;68(3):885-923. doi: 10.3233    PDF

Smith CJ, Ashford JW. APOE e4 Allele-associated Alzheimers disease risk is consistent with increased lifetime exposure to a neurotoxic process. J Syst Integr Neurosci, 2017 Volume 3(4): 1-4.    PDF

Adamson MM, Landy KM, Duong S, Fox-Bosetti S, Ashford JW, Murphy GM, Weiner M, Taylor JL. Apolipoprotein E varepsilon4 influences on episodic recall and brain structures in aging pilots. Neurobiol Aging. 2008 Aug 27.    PDF

Raber J, Huang, Y, Ashford ApoE genotype accounts for the vast majority of AD risk and AD neuropathology. Neurobiology of Aging 25(5):641-50 2004.    PDF

Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology.
Journal of Molecular Neuroscience 23:155-163, 2004.    PDF

Teter B, Ashford JW. Neuroplasticity in Alzheimer's disease. J Neurosci Res. 2002 Nov 1;70(3):402-    PDF

Ashford JW, Mortimer JA. Non-familial Alzheimer's disease is mainly due to genetic factors. J Alzheimer's Dis. 2002 Jun;4(3):169-77.    PDF

Ashford JW. ApoE4: is it the absence of good or the presence of bad? J Alzheimer's Dis. 2002 Jun;4(3):141-3. (No abstract available).    PDF

Prevention and Treatment of Alzheimer's disease

Ashford, 2024 update of recommendations made in 2002 for the Long Island Alzheimer Foundation (LIAF) for Alzheimer prevention.

PowerPoint slides discussing Alzheimer's disease and prevention.

Handbook of Prevention and Alzheimer's Disease
Volume 10 of Advances in Alzheimer's Disease
Publication date: February 2024
Editors: Raji, C.A., Leng, Y., Ashford, J.W., Khalsa, D.S.

Handbook of Intervention and Alzheimer's Disease,
Volume 11 of Advances in Alzheimer's Disease
Publication date: February 2024
Editors: Raji, C.A., Leng, Y., Ashford, J.W., Khalsa, D.S.

Articles related to treatment of Alzheimer's disease

Ashford JW. Neuroplasticity: The Critical Issue for Alzheimer's Disease and Links to Obesity and Depression. Am J Geriatr Psychiatry. 2023 Jul 15:S1064-7481(23)00354-8. doi: 10.1016    PDF

Ashford JW. Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2020 Mar 31;94(13):593-594. doi: 10.1212    PDF

Ashford JW. Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions. J Alzheimers Dis. 2019;67(3):923-930.    PDF

Sun W, Lee S, Huang X, Liu S, Inayathullah M, Kim KM, Tang H, Ashford JW, Rajadas J. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. Sci Rep. 2016 Oct 6;6:34784.    PDF

Ashford JW. Trace Amyloid Back to Precursor Protein, And then go farther down that pathway to find Alzheimer's cause - MedPage Today - THE GUPTA GUIDE    PDF

Ashford JW. Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. J Alzheimers Dis. 2015;47(1):149-56.    PDF

Lazzeroni LC, Halbauer JD, Ashford JW, Noda A, Hernandez B, Azor V, Hozack N, Hasson N, Henderson VW, Yesavage JA, Tinklenberg JR. Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008. J Alzheimers Dis. 2013;36(4):791-8.    PDF

Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry. 2007 Nov;15(11):953-60.    PDF

Ashford JW, Atwood CS, Blass JP, Bowen RL, Finch CE, Iqbal K, Joseph JA, Perry G. What is aging? What is its role in Alzheimer's disease? What can we do about it? Journal of Alzheimers Disease 7(3):247-53; discussion 255-62 2005.    PDF

Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF. Physostigmine and its effect on six patients with dementia.
Am J Psychiatry. 1981 Jun;138(6):829-30.    PDF

Articles related to the neuropathology of Alzheimer's disease, brain imaging and autopsy studies

Ashford JW. The Dichotomy of Alzheimer's Disease Pathology: Amyloid-beta and Tau. J Alzheimers Dis. 2019;68(1):77-83.    PDF

Ashford JW, Bayley PJ. Retrogenesis: a model of dementia progression in Alzheimer's disease related to neuroplasticity. J Alzheimers Dis. 2013;33(4):1191-3. J Alzheimers Dis. 2019;68(1):77-83.    PDF

J Wesson Ashford, Ahmad Salehi, Ansgar Furst, Peter Bayley, Giovanni B Frisoni, Clifford R Jack Jr, Osama Sabri, Maheen M Adamson, Kerry L Coburn, John Olichney, Norbert Schuff, Daniel Spielman, Steven D Edland, Sandra Black, Allyson Rosen, David Kennedy, Michael Weiner, George Perry.J Alzheimers Dis. Imaging the Alzheimer brain. 2011;26 Suppl 3(0 3):1-27.    PDF

Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000 Aug 8;55(3):370-6.    PDF

Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease.
J Nucl Med. 2000 Jan;41(1):57-64. PDF

Shih WJ, Ashford JW, Coupal JJ, Ryo YU, Stipp V V, Magoun SL, Gross K. Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer's disease
Clin Nucl Med. 1999 Oct;24(10):773-7. PDF

Shih WJ, Wilson D, Stipp V, Ashford JW. Heterogenous uptake on brain SPECT. Semin Nucl Med. 1999 Jan;29(1):85-8. PDF

Ashford JW, Mattson M, Kumar V. Neurobiological systems disrupted by Alzheimer's disease and molecular biological theories of vulnerability.
In Advances in the Diagnosis and Treatment of Alzheimer's Disease. Kumar V. Eisdorfer C. eds, Springer Publishing Company, New York, 1998:53-89.    PDF

Ashford JW, Soultanian NS, Zhang SX, Geddes JW. Neuropil threads are collinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain.
J Neuropathol Exp Neurol. 1998 Oct;57(10):972-8. pdf
See Figure 1 in color (196K).

Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
Pharmacotherapy. 1998 Sep-Oct;18(5):1129-32.

Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, Ashford JW, Smith CD, Wekstein DR, Markesbery WR, Orazem J, Ruzicka BB, Mas J, Gulanski B. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
J Clin Pharmacol. 1998 Mar;38(3):236-45.

Shih WJ, Davis DG, Stipp V, Ashford W, Magoun S. Bilateral perfusion defect/hypoperfusion in temporal and parietal regions on brain SPECT.
Semin Nucl Med. 1998 Apr;28(2):192-3. PDF

Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease.
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S99-105.

Older studies

Ashford, J.W., and Miller, T.W. Effect of Trazodone on Sleep in PTSD Patients.
Journal of Contemporary Psychotherapy, 1996, 26(3):221-233. PDF

Semla TP, Cohen D, Freels S, Paveza GJ, Ashford JW, Gorelick P, Luchins D, Eisdorfer C. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease.
Pharmacotherapy. 1995 Jul-Aug;15(4):495-501.

Smith CJ, Lippiello PM, Ashford JW. Smoking, Alzheimer's disease, and confounding with genes.
Lancet. 1995 Apr 22;345(8956):1054. No abstract available.

Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology.
Neurobiol Aging. 1995 Mar-Apr;16(2):187-98.

Cohen D, Eisdorfer C, Gorelick P, Paveza G, Luchins DJ, Freels S, Ashford JW, Semla T, Levy P, Hirschman R. Psychopathology associated with Alzheimer's disease and related disorders.
J Gerontol. 1993 Nov;48(6):M255-60.

Coburn KL, Ashford JW, Moreno MA. Delayed late component of visual global field power in probable Alzheimer's disease.
J Geriatr Psychiatry Neurol. 1993 Apr-Jun;6(2):72-7.

Semla TP, Cohen D, Paveza G, Eisdorfer C, Gorelick P, Luchins D, Hirschman R, Freels S, Levy P, Ashford JW, et al. Drug use patterns of persons with Alzheimer's disease and related disorders living in the community.
J Am Geriatr Soc. 1993 Apr;41(4):408-13.

Cohen D, Eisdorfer C, Gorelick P, Luchins D, Freels S, Semla T, Paveza G, Shaw H, Ashford JW. Sex differences in the psychiatric manifestations of Alzheimer's disease.
J Am Geriatr Soc. 1993 Mar;41(3):229-32.

Hargrave R, Ashford JW. Phenelzine treatment of depression in Parkinson's disease.
Am J Psychiatry. 1992 Dec;149(12):1751-2. No abstract available.

Freels S, Cohen D, Eisdorfer C, Paveza G, Gorelick P, Luchins DJ, Hirschman R, Ashford JW, Levy P, Semla T, et al. Functional status and clinical findings in patients with Alzheimer's disease.
J Gerontol. 1992 Nov;47(6):M177-82.

Brewer GJ, Ashford JW. Human serum stimulates Alzheimer markers in cultured hippocampal neurons.
J Neurosci Res. 1992 Nov;33(3):355-69.

Paveza GJ, Cohen D, Eisdorfer C, Freels S, Semla T, Ashford JW, Gorelick P, Hirschman R, Luchins D, Levy P. Severe family violence and Alzheimer's disease: prevalence and risk factors.
Gerontologist. 1992 Aug;32(4):493-7.    PDF

Luchins DJ, Cohen D, Hanrahan P, Eisdorfer C, Paveza G, Ashford JW, Gorelick P, Hirschman R, Freels S, Levy P, et al. Are there clinical differences between familial and nonfamilial Alzheimer's disease?
Am J Psychiatry. 1992 Aug;149(8):1023-7.

Eisdorfer C, Cohen D, Paveza GJ, Ashford JW, Luchins DJ, Gorelick PB, Hirschman RS, Freels SA, Levy PS, Semla TP, et al. An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's disease.
Am J Psychiatry. 1992 Feb;149(2):190-4.    PDF

Ashford JW, Kumar V, Barringer M, Becker M, Bice J, Ryan N, Vicari S. Assessing Alzheimer severity with a global clinical scale.
Int Psychogeriatr. 1992 Summer;4(1):55-74.    PDF

Coburn KL, Ashford JW, Moreno MA. Visual evoked potentials in dementia: selective delay of flash P2 in probable Alzheimer's disease.
J Neuropsychiatry Clin Neurosci. 1991 Fall;3(4):431-5.

Cohen D, Paveza G, Levy PS, Ashford JW, Brody JA, Eisdorfer C, Gorelick P, Hirschman R, Luchins D, Trozzolo T, et al. An Alzheimer's disease patient registry: the Prototype Alzheimer Collaborative Team (PACT).
Aging (Milano). 1990 Sep;2(3):312-6. No abstract available.

Coburn KL, Ashford JW, Fuster JM. Visual response latencies in temporal lobe structures as a function of stimulus information load.
Behav Neurosci. 1990 Feb;104(1):62-73.    PDF

Parks, R.W., Crockett, D.J., Tuokko, H., Beattie, B.L., Ashford, J.W., Coburn, K.L., Zec, R.F., Becker, R.E., McGeer, P.L. and McGeer, E.G. Neuropsychological "systems efficiency" and positron emission tomography. Journal of Neuropsychiatry. 1:269-282. PDF

Small GW, Kuhl DE, Riege WH, Fujikawa DG, Ashford JW, Metter EJ, Mazziotta JC. Cerebral glucose metabolic patterns in Alzheimer's disease. Effect of gender and age at dementia onset.
Arch Gen Psychiatry. 1989 Jun;46(6):527-32.

Ashford JW, Sherman KA, Kumar V. Advances in Alzheimer therapy: cholinesterase inhibitors.
Neurobiol Aging. 1989 Jan-Feb;10(1):99-105. PDF

Parks RW, Crockett DJ, Tuokko H, Beattie BL, Ashford JW, Coburn KL, Zec RF, Becker RE, McGeer PL, McGeer EG. Neuropsychological "systems efficiency" and positron emission tomography.
J Neuropsychiatry Clin Neurosci. 1989 Summer;1(3):269-82. Review.

Kumar V, Smith RC, Sherman KA, Ashford W, Murphy J, Giacobini E, Colliver J. Cortisol responses to cholinergic drugs in Alzheimer's disease.
Int J Clin Pharmacol Ther Toxicol. 1988 Oct;26(10):471-6.

Ashford JW, Fuster JM. Occipital and inferotemporal responses to visual signals in the monkey.
Exp Neurol. 1985 Nov;90(2):444-66.    PDF

Ashford JW, Coburn KL, Fuster JM. The elgiloy microelectrode: fabrication techniques and characteristics.
J Neurosci Methods. 1985 Sep;14(4):247-52.

Ashford JW, Jarvik L. Alzheimer's disease: does neuron plasticity predispose to axonal neurofibrillary degeneration?
N Engl J Med. 1985 Aug 8;313(6):388-9. PDF

Fuster JM, Willey TJ, Riley DM, Ashford JW. Effects of ethanol on visual evoked responses in monkeys performing a memory task.
Electroencephalogr Clin Neurophysiol. 1982 Jun;53(6):621-33.

Ashford JW, Schulz C, Walsh GO. Violent automatism in a partial complex seizure. Report of a case.
Arch Neurol. 1980 Feb;37(2):120-2.

Ashford JW, Ford CV. Use of MAO inhibitors in elderly patients.
Am J Psychiatry. 1979 Nov;136(11):1466-7. No abstract available.